Editorial commentary: Aspirin resistance: More emphasis on definition and appropriate use of platelet function tests is needed

Archives of Medical Science

Volumn 5, Issue 4, 2009, Pages 539-541

  Gasparyan, Armen Y ^a  

^a DUDLEY GROUP OF HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ARACHIDONIC ACID; COLLAGEN; VON WILLEBRAND FACTOR;

ACETYLATION; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR RISK; CORONARY STENT; DRUG RESISTANCE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; NOTE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; SHEAR STRESS; STROKE; THROMBOCYTE FUNCTION;

EID: 75349104491     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (19)

1. Barrett NE, Holbrook L, Jones S, et al. Future innovations in anti-platelet therapies. Br J Pharmacol 2008; 154: 918-39.
2. Siddique A, Butt M, Shantsila E, Lip GY. New antiplatelet drugs: beyond aspirin and clopidogrel. Int J Clin Pract 2009; 63: 776-89.
3. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003; 110: 255-8.
4. Gasparyan AY, Mohammad-Hasani MR, Hassoun H, Darban H. Recent advances in cardiovascular medicine: the tenth Iranian congress on cardiovascular update. Arch Iran Med 2009; 12: 213-6.
5. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51: 1829-43.
6. Antithrombotic Trialists' (ATT) Collaboration; Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
7. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
8. Sofi F, Marcucci R, Gori AM, Abbate R, Gensini GF. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events - a meta-analysis. Int J Cardiol 2008; 128: 166-71.
9. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007; 153: 175-81.
10. Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 2009; 103 (3 Suppl): 27A-34A.
11. Lee SW, Park SW, Hong MK, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005; 46: 1833-7.
12. Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009; 157: 733-9.
13. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336: 195-8.
14. Anfossi G, Russo I, Trovati M. Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome. Curr Vasc Pharmacol 2008; 6: 313-28.
15. Dasgupta A, Steinhubl SR, Bhatt DL, et al.; CHARISMA Investigators. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am J Cardiol 2009; 103: 1359-63.
16. Malek LA, Grabowski M, Spiewak M, Filipiak KJ, et al. Relation between impaired antiplatelet response to clopidogrel and possible pleiotropic effects. J Thromb Thrombolysis 2007; 24: 301-5.
17. Catakoglu AB, Aytekin S, Celebi H, et al. The influence of aspirin resistance on non-fatal coronary events following percutaneous coronary interventions. Arch Med Sci 2009; 5: 531-8.
18. Chakroun T, Gerotziafas G, Robert F, et al. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 2004; 124: 80-5.
19. Schwartz KA, Schwartz DE, Barber K, Reeves M, De Franco AC. Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med 2008; 6: 46.